|Articles|November 16, 2020
- Pharmaceutical Executive-11-01-2020
- Volume 40
- Issue 11
Pharmaceutical Executive, November 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
Synthetic Biology and the Environmentalmost 5 years ago
Measuring Pharma’s Wider Mandatealmost 5 years ago
Patients as the North Staralmost 5 years ago
Going Public During Lockdown: IPO Insights from Five Biotechnology CFOsalmost 5 years ago
A Rare-Disease Must? Building Long-Term Relationshipsalmost 5 years ago
Making Remote Work a Success Beyond COVIDalmost 5 years ago
CRISPR for Diversity, and Humanity’s, Sakealmost 5 years ago
Expediting the Cancer Treatment Pathalmost 5 years ago
Vaccine Authorization, Distribution Raise Multiple Challengesalmost 5 years ago
EU Leaders in High-Stakes Gamble on COVID ResponsesNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics
2
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
3
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
4
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
5
